Michael Ward, APRN, AGACNP-BC

Aging is inevitable. Preventable decline is not.

A DO-HEALTH post hoc analysis found omega-3 produced small changes in several epigenetic aging clocks, roughly 3 months over 3 years. That is a biomarker effect, not proof of longer life. pubmed.ncbi.nlm.nih.gov/3990… What outcome matters most to you?

Biological-age tests can be interesting, but results differ by method and may not change care. Start with validated risk factors and functional measures before paying for exotic dashboards. What action would a biological-age result actually change?

A younger biomarker is not the same thing as a longer, healthier life. Surrogates can guide research, but outcomes still matter. Which impressive-sounding metric deserves more skepticism?

In TRAVERSE, prostate events were infrequent and did not differ significantly between testosterone and placebo. Men at high prostate risk were excluded. pubmed.ncbi.nlm.nih.gov/3815… How should that shape counseling?

When testosterone is appropriate, follow-up matters: symptoms, hematocrit, blood pressure, adverse effects, and prostate monitoring based on age and risk. Treatment without a monitoring plan is incomplete care. What should trigger reassessment?

Monitoring is not bureaucracy. It is how we learn whether a treatment is helping, harming, or no longer worth the tradeoff. What therapy in your life has a clear follow-up plan?

TRAVERSE found testosterone noninferior to placebo for major CV events in selected men with hypogonadism, but atrial fibrillation, kidney injury, and pulmonary embolism were higher. pubmed.ncbi.nlm.nih.gov/3732… What does informed consent require?

Testosterone therapy is not a general anti-aging shortcut. Proper evaluation includes symptoms, repeat morning levels, reversible causes, fertility goals, prostate considerations, blood counts, and cardiovascular risk. Which step is easiest to overlook?

Hormone care should begin with symptoms, context, and goals, not with chasing a number from social media. What would a thoughtful evaluation help you understand?

At 50, I’m no longer chasing heavier lifts. Instead, the focus is on proper form with slowed concentric and eccentric movements, combined with mobility, flexibility, and power movements. This strategy will help me preserve muscle mass, maintain strength, improve joint health, and enhance my ability to move efficiently as I age. The goal is no longer just to look strong. It’s to remain strong, mobile, explosive, and physically independent for decades to come. – at Burleson, TX

In a large observational cohort, coronary calcium severity identified people most likely to benefit from statins; no benefit was seen in those with CAC 0 during follow-up. This was not randomized. pubmed.ncbi.nlm.nih.gov/3040… Would the result change your decision?

Good decisions rarely come from one number alone. Context matters: age, history, values, competing risks, and what a result would actually change. Which health test would be useful only if it changed your next step?

One year after stopping semaglutide in a trial extension, participants regained about two-thirds of their prior weight loss and cardiometabolic gains moved toward baseline. pubmed.ncbi.nlm.nih.gov/3544… Should obesity care be treated more like other chronic care?

Anti-obesity medication works best inside a durable care plan: nutrition, strength, sleep, side-effect management, and a strategy for continuation or transition. What support would make progress easier to maintain?

Chronic disease deserves long-term thinking. Starting a treatment can be difficult; planning how to sustain the gains may be even more important. Where do you need a maintenance plan, not another reset?

A randomized crossover study found frequent short walking breaks improved post-meal glucose and systolic blood pressure compared with prolonged sitting. Acute responses do not guarantee long-term benefit. pubmed.ncbi.nlm.nih.gov/3672… What movement dose fits your day?